GtoPdb is requesting financial support from commercial users. Please see our sustainability page for more information.
|
Synonyms: PHI-101 | PHI101
Compound class:
Synthetic organic
Comment: Lasmotinib is the INN for a tyrosine kinase inhibitor. A structure match in PubChem linked the INN to the company research code PHI-101 (Pharos iBio). PHI-101 has been reported as a FMS-like tyrosine kinase 3 (FLT3) inhibitor [1] and as a checkpoint kinase 2 (Chk2) inhibitor [2], and both of these mechanisms are confirmed by information presented on Pharos iBio's development pipeline page [3]. PHI-101 is proposed for the treatment of various types of cancer. At the time of writing (Feb 2025) the chemical structure of PHI-101 had not been formally disclosed.
|
|
|||||||||||||||||||||||||||||||||||
Classification ![]() |
|
| Compound class | Synthetic organic |
IUPAC Name ![]() |
| 3-(carbamoylamino)-5-[2-(3-fluorophenyl)ethynyl]-N-[(3S)-piperidin-3-yl]thiophene-2-carboxamide |
International Nonproprietary Names ![]() |
|
| INN number | INN |
| 13351 | lasmotinib |
Synonyms ![]() |
| PHI-101 | PHI101 |
Database Links ![]() |
|
| CAS Registry No. | 2127107-15-5 (source: WHO INN record) |
| ChEMBL Ligand | CHEMBL4802136 |
| DrugBank Ligand | DB17237 |
| GtoPdb PubChem SID | 507750379 |
| PubChem CID | 130358571 |
| Search Google for chemical match using the InChIKey | ULVAGWVTXBTFRN-AWEZNQCLSA-N |
| Search Google for chemicals with the same backbone | ULVAGWVTXBTFRN |
| Search PubMed clinical trials | lasmotinib |
| Search PubMed titles | lasmotinib |
| Search PubMed titles/abstracts | lasmotinib |
| UniChem Compound Search for chemical match using the InChIKey | ULVAGWVTXBTFRN-AWEZNQCLSA-N |
| UniChem Connectivity Search for chemical match using the InChIKey | ULVAGWVTXBTFRN-AWEZNQCLSA-N |